Sarepta Therapeutics, Inc.
เพิ่มขึ้น

$SRPT Oversold at Support

SRPT RSI looking oversold on the daily chart, held trend line support well today. Expecting a bounce in the near/medium term.
Targeting $160 at least by next earnings release late October.




Note: Informational analysis, not investment advice.
Bullish PatternsChart PatternsSRPTTrend Analysis

และใน:

คำจำกัดสิทธิ์ความรับผิดชอบ